Scotland's Mironid is moving from discovery into drug development, armed with fresh venture capital from Roche Holding AG and a promising candidate that could shake up the autosomal dominant polycystic kidney disease (ADPKD) space.
Key Takeaways:
- Mironid has raised £35m in total to advance its preclinical ADPKD candidate
- Roche Ventures has become an investor in the Scottish biotech
- The company hopes to develop a drug that could offer
Mironid, which raised £4.3m in June 2016 in its Series A financing, has announced an extension of that round, bringing the total amount raised since inception to £35m ($43.6m)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
